ERCC1 rs11615 Single Nucleotide Polymorphism in Bladder Cancer Patients and Safety Outcomes of Cisplatin-Based Chemotherapy

Objectives To investigate the relationship between single nucleotide polymorphism (SNP) of excision repair cross-complementation group 1 (ERCC1) rs11615 and the safety outcomes of cisplatin-based adjuvant chemotherapy in post-cystectomy bladder cancer patients. Methods This pilot single-center retrospective cohort research study involved 25 patients with muscle-invasive bladder cancer who were admitted to the Urology and Nephrology Center (UNC), Mansoura University, Egypt between January and December 2016. The study tried to reveal the association between SNP rs11615 in ERCC1 gene and the change from baseline characteristics in a median of 96 weeks follow-up in blood, renal, and hepatic biochemical parameters. Results Univariate analysis of the association between rs11615 and post-chemotherapy changes in uric acid and hemoglobin levels showed a statistically significant relationship. Conclusion These findings hint at possible genetic influences in response to chemotherapy, necessitating further research to understand the mechanisms and potential clinical implications. This could lead to personalized treatment plans enhancing patient care and outcomes.